TEST:

DLBCL-COO Assay

Results Ninety-one patients were registered into current study, 43 (47.3%) of which received BTK inhibitors (ibrutinib, acalabrutinib, or zanubrutinib) and/or lenalidomide chemo-free therapies (chemo-free therapy) and 48 (52.7%) of which received BTK inhibitors (ibrutinib, acalabrutinib, or zanubrutinib) and/or lenalidomide combo therapy with cytotoxic regimen (combo therapy). The most common administrated cytotoxic regimen with BTK inhibitors and/or lenalidomide were: R2 (rituximab plus lenalidomide) in 11 patients, lenalidomide in 10 patients and R2-GEMOX in 9 patients...A considerable proportion GCB subtype R/R DLBCL received BTK inhibitor and/or lenalidomide. Molecular subtyping predicts the clinical benefit for patients with combo therapies, instead of the chemo-free therapies, in which heavier prior treatment may significantly impact the clinical outcome.